EMSF Lisboa

In partnership with PR Newswire since 1974

Alamar Biosciences launches the NULISAqpcr™ Custom Assay Development Kit to advance the development of novel biomarker assays for clinical research

Alamar-NULISAqpcr

PR Newswire

Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is proud to announce the release of the NULISAqpcr™ Custom Assay Development Kit, a groundbreaking product that empowers researchers to create highly sensitive and precise biomarker assays tailored to their specific research needs, expanding application of the NULISA™ technology to the broader biomarker research community.